Monday, December 1, 2025 12/1/2025

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer

Award Number: P50CA168504
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/17/2013
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer - PROJECT SUMMARY The Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Breast Cancer seeks to improve the understanding and treatment of breast cancer using an innovative and highly translational approach. The application consists of four projects, three cores, a developmental research program (DRP) and a career enhancement programs (CEP). Each project addresses a fundamental challenge that results in premature mortality or substantial morbidity. Project 1 brings together outstanding investigators to study mechanisms of resistance to CDK4/6 inhibitors. In estrogen receptor-positive breast cancer, we hypothesize that CDK2 hyperactivation is a cause of acquired resistance to CDK4/6 inhibitors. Elegant preclinical work will be complemented by a clinical study in which paired biopsies are obtained prior to initiation of CDK4/6 inhibitors and when resistance develops. In triple-negative breast cancer, we will evaluate the possibility that lysosomal sequestration of CDK4/6 inhibitors limits their therapeutic efficacy. In preclinical work, we will determine if this sequestration can be reversed administering chloroquine and will also conduct a trial of palbociclib/chloroquine in RB-intact triple-negative disease. Project 2 uses two “co-clinical” trials – running randomized human trials and mouse experiments largely in parallel – to study two novel therapeutic approaches to enhance the anti- tumor immune response against HER2-positive breast cancers (CDK4/6 inhibition and dual PDL1 and 4-1BB targeting). Both approaches are based on our compelling preclinical data, and will include local and international collaborators. Project 3 tackles the challenge of breast cancer brain metastases. Leveraging our unique collection of xenografts derived from resected human brain metastases, and our experience conducting brain metastasis-specific trials, we will test the biologic and clinical impact of two novel systemic therapy regimens. Project 4 is focused on triple-negative breast cancer. We will perform comprehensive preclinical studies and clinical trials to determine whether targeted therapies can sensitize triple-negative tumors to immunotherapy. We will evaluate combinations of either PARP inhibitors or BET bromodomain inhibitors with immune checkpoint blockade. Core A, the Administrative Core, is the epicenter of scientific, fiscal and administrative oversight. It will lead efforts in planning and communication, and also houses the Patient Advocacy Committee. Core A will ensure that existing DF/HCC structures support the SPORE clinical research efforts. Core B, the Biostatistics and Computational Biology core, provides specialized expertise in biostatistics and management of genomic data. Core C, the Biospecimen and Pathology Core, will maintain tissue/blood repositories for the SPORE projects and for investigators outside of the SPORE. It also provides critical pathology services for the projects and will perform cutting edge assays. Core C also houses the Immuno-Oncology Sub Core. The DRP and CEP identify novel approaches to translational questions in breast cancer and support young investigators. Our SPORE in Breast Cancer is poised to make substantial contributions over the next five years and beyond.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Centers Support Grants	000	10	11/21/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $2,607,297 )
2025	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Centers Support Grants	000	11	9/8/2025	COMPETING CONTINUATION	$2,607,297
														Subtotal = $2,607,297

Issue Date FY: 2023 ( Subtotal = $2,302,230 )
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	10	7/21/2023	NON-COMPETING CONTINUATION	$2,302,230
2023	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	9	12/13/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,302,230

Issue Date FY: 2022 ( Subtotal = $2,210,645 )
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	003	9	9/21/2022	NON-COMPETING CONTINUATION	$49,889
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	002	9	7/18/2022	NON-COMPETING CONTINUATION	$2,160,756
2022	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	8	5/5/2022	NON-COMPETING CONTINUATION	$0
2022	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	8	3/4/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,210,645

Issue Date FY: 2021 ( Subtotal = $2,345,277 )
2021	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	8	7/22/2021	NON-COMPETING CONTINUATION	$2,345,277
2021	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	7	12/10/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,345,277

Issue Date FY: 2020 ( Subtotal = $2,382,404 )
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	002	7	7/13/2020	NON-COMPETING CONTINUATION	$2,382,404
2020	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	6	1/21/2020	COMPETING CONTINUATION	$32,289
2020	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	5	1/21/2020	NON-COMPETING CONTINUATION	-$32,289
														Subtotal = $2,382,404

Issue Date FY: 2019 ( Subtotal = $2,482,574 )
2019	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	002	6	7/5/2019	COMPETING CONTINUATION	$2,482,574
2019	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	5	3/18/2019	NON-COMPETING CONTINUATION	$0
2019	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	5	7/1/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,482,574

Issue Date FY: 2017 ( Subtotal = $2,051,965 )
2017	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	002	5	7/26/2017	NON-COMPETING CONTINUATION	$1,936,965
2017	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	005	5	9/20/2017	NON-COMPETING CONTINUATION	$115,000
2017	2016	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	4	2/17/2017	EXTENSION WITH OR WITHOUT FUNDS	$481,459
2017	2016	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	004	4	8/8/2017	EXTENSION WITH OR WITHOUT FUNDS	$5
2017	2015	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	003	3	8/8/2017	NON-COMPETING CONTINUATION	-$5
2017	2015	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	3	2/17/2017	NON-COMPETING CONTINUATION	-$481,459
														Subtotal = $2,051,965

Issue Date FY: 2016 ( Subtotal = $2,161,168 )
2016	2016	DANA-FARBER CANCER INSTITUTE	44 BINNEY STREET	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	4	7/20/2016	EXTENSION WITH OR WITHOUT FUNDS	$2,161,168
														Subtotal = $2,161,168

Issue Date FY: 2015 ( Subtotal = $2,135,538 )
2015	2015	DANA-FARBER CANCER INSTITUTE	44 BINNEY STREET	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	3	8/10/2015	NON-COMPETING CONTINUATION	$2,135,538
														Subtotal = $2,135,538

Issue Date FY: 2014 ( Subtotal = $2,197,001 )
2014	2014	DANA-FARBER CANCER INSTITUTE	44 BINNEY STREET	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	2	8/14/2014	NON-COMPETING CONTINUATION	$2,162,001
2014	2014	DANA-FARBER CANCER INSTITUTE	44 BINNEY STREET	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	2	9/15/2014	NON-COMPETING CONTINUATION	$35,000
														Subtotal = $2,197,001

Issue Date FY: 2013 ( Subtotal = $2,150,500 )
2013	2013	DANA-FARBER CANCER INSTITUTE	44 BINNEY STREET	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	1	9/17/2013	NEW	$2,150,500
														Subtotal = $2,150,500

Grand Total All Awards = $25,026,599

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer

Award Number: P50CA168504

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/17/2013

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer